科兴称相隔三周接种两剂疫苗 有效率近七成
中国科兴生物(SVA.US)公布,於巴西的最新临床测试结果显示,研发的新型冠状病毒疫苗有效率接近70%。巴西当局早前批出紧急使用许可予科兴和英国阿斯利康(AZN.US)药厂疫苗。
发言人指,1,394名参与者相隔三星期接种两剂疫苗,有效率近70%。而巴西研究人员上周公布的有效率50.4%,是基於超过9,000名志愿者的测试结果,志愿者大部分相隔两星期接种两剂疫苗,但有少部分志愿者因为不同原因,较迟才接受第二剂注射。(ek/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.